EA201591607A1 - Гетероциклические соединения, применимые в лечении заболеваний - Google Patents
Гетероциклические соединения, применимые в лечении заболеванийInfo
- Publication number
- EA201591607A1 EA201591607A1 EA201591607A EA201591607A EA201591607A1 EA 201591607 A1 EA201591607 A1 EA 201591607A1 EA 201591607 A EA201591607 A EA 201591607A EA 201591607 A EA201591607 A EA 201591607A EA 201591607 A1 EA201591607 A1 EA 201591607A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diseases
- treatment
- heterocyclic compounds
- fibrosis
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Описаны гетероциклические соединения, представляющие собой лиганды рецепторов лизофосфатидной кислоты, применимые в лечении заболеваний и состояний, зависимых от рецепторов лизофосфатидной кислоты, в том числе, без ограничения, заболеваний, включающих фиброз, такой как фиброз сердца, почки, печени и легкого, и склеродермию; воспалительных заболеваний, таких как диабетическая нефропатия и воспалительное заболевание кишечника; заболеваний глаз, таких как заболевания, включающие дегенерацию сетчатки; нервных заболеваний, таких как зуд и боль. Неограничивающие примеры этих соединений включают (RS)-3-циклопропил-2-{4-[3-метил-4-((R)-1-фенилэтоксикарбониламино)изоксазол-5-ил]бензилокси}пропионовую кислоту и (R)-1-(4'-{5-[1-(2-хлорфенил)этоксикарбониламино]-4-фторпиразол-1-ил}-2-фтордифенил-4-ил)циклопропанкарбоновую кислоту.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361801231P | 2013-03-15 | 2013-03-15 | |
US201361801426P | 2013-03-15 | 2013-03-15 | |
US201361827409P | 2013-05-24 | 2013-05-24 | |
PCT/US2014/030712 WO2014145873A2 (en) | 2013-03-15 | 2014-03-17 | Heterocyclic compounds useful in the treatment of disease |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201591607A1 true EA201591607A1 (ru) | 2016-05-31 |
EA201591607A8 EA201591607A8 (ru) | 2018-03-30 |
EA033923B1 EA033923B1 (ru) | 2019-12-10 |
Family
ID=51538557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591607A EA033923B1 (ru) | 2013-03-15 | 2014-03-17 | Гетероциклические соединения, применимые в лечении заболеваний |
Country Status (16)
Country | Link |
---|---|
US (5) | US10000459B2 (ru) |
EP (1) | EP2988743B1 (ru) |
JP (2) | JP6482086B2 (ru) |
KR (1) | KR102090231B1 (ru) |
CN (2) | CN105142635B (ru) |
AU (3) | AU2014232383B2 (ru) |
BR (2) | BR112015023267B1 (ru) |
CA (1) | CA2906931C (ru) |
DK (1) | DK2988743T3 (ru) |
EA (1) | EA033923B1 (ru) |
ES (1) | ES2855173T3 (ru) |
HK (1) | HK1221167A1 (ru) |
MX (2) | MX2015013303A (ru) |
PT (1) | PT2988743T (ru) |
SG (3) | SG11201507459YA (ru) |
WO (1) | WO2014145873A2 (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201507459YA (en) * | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
JPWO2017086430A1 (ja) * | 2015-11-20 | 2018-09-06 | 宇部興産株式会社 | Nashの治療又は予防のための医薬組成物 |
KR102292989B1 (ko) | 2017-03-29 | 2021-08-26 | 재단법인 아산사회복지재단 | S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물 |
US11312706B2 (en) | 2017-12-19 | 2022-04-26 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as LPA antagonists |
WO2019126099A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
US11261180B2 (en) | 2017-12-19 | 2022-03-01 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as LPA antagonists |
TWI830713B (zh) | 2017-12-19 | 2024-02-01 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之***n-連接之胺甲醯基環己基酸 |
CN111479807A (zh) | 2017-12-19 | 2020-07-31 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑吖嗪 |
US11180488B2 (en) | 2017-12-19 | 2021-11-23 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists |
KR20200100753A (ko) * | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아졸 |
ES2962367T3 (es) * | 2017-12-19 | 2024-03-18 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) |
CN112041302A (zh) * | 2017-12-19 | 2020-12-04 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
CA3104465A1 (en) | 2018-06-18 | 2019-12-26 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US20240122934A1 (en) * | 2019-10-16 | 2024-04-18 | University Of South Florida | Compositions and methods of treatment for inhibiting capillary tube regression |
CA3158743A1 (en) | 2019-11-15 | 2021-05-20 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
IL298082A (en) | 2020-06-03 | 2023-01-01 | Gilead Sciences Inc | lpa receptor antagonists and uses thereof |
WO2021247215A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
EP4182301A1 (en) * | 2020-07-16 | 2023-05-24 | Chiesi Farmaceutici S.p.A. | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
MX2023001812A (es) * | 2020-08-11 | 2023-06-19 | Viva Star Biosciences Ltd | Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa. |
WO2022240879A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2308B1 (en) | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | Derivatives of phenylpyrmidine |
AU2001232340A1 (en) | 2000-02-18 | 2001-08-27 | Kirin Beer Kabushiki Kaisha | Novel isoxazole and thiazole compounds and use thereof as drugs |
EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
US20060148858A1 (en) | 2002-05-24 | 2006-07-06 | Tsuyoshi Maekawa | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity |
KR20060017865A (ko) | 2003-06-11 | 2006-02-27 | 상꾜 가부시키가이샤 | 환상 3급 아민 화합물 |
WO2005012269A1 (ja) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
EP1682494A4 (en) | 2003-10-30 | 2006-11-08 | Merck & Co Inc | ARALKYLAMINES AS MODULATORS OF CANNABINOID RECEPTORS |
ES2314633T3 (es) | 2004-03-26 | 2009-03-16 | F. Hoffmann-La Roche Ag | Tetrahidrocarbazoles y derivados. |
WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
BRPI0612287A8 (pt) | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
TW200803740A (en) * | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
WO2008062739A1 (fr) | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Pyrazoles et leur utilisation en tant que médicaments |
EP2202226B1 (en) | 2007-10-18 | 2013-06-05 | Kumiai Chemical Industry CO., LTD. | 3-alkoxy-1-phenylpyrazole derivative and pest control agent |
WO2010004507A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
JP2013501064A (ja) * | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス,インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
JP4683154B2 (ja) | 2009-08-12 | 2011-05-11 | 横浜ゴム株式会社 | 冷媒移送用ホース |
GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
WO2011159632A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
WO2011159635A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
US20120031985A1 (en) | 2010-08-09 | 2012-02-09 | Terry Lien Do | Fault tolerant appliance |
AU2011338561A1 (en) | 2010-12-07 | 2013-07-25 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis |
NO2648726T3 (ru) | 2010-12-07 | 2018-09-01 | ||
CN103443098B (zh) | 2011-01-30 | 2016-03-16 | 广州源生医药科技有限公司 | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 |
US8975235B2 (en) * | 2011-03-20 | 2015-03-10 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
SG11201405918XA (en) | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
WO2013189864A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-alkyltriazole compounds as lpar antagonists |
UA109867C2 (ru) | 2012-06-20 | 2015-10-12 | Ф. Хоффманн-Ля Рош Аг | Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar) |
CN104395299A (zh) | 2012-06-20 | 2015-03-04 | 霍夫曼-拉罗奇有限公司 | 作为lpar拮抗剂的n-芳基***化合物 |
MX369801B (es) | 2012-12-28 | 2019-11-21 | Ube Industries | Compuesto heterociclico sustituido con halogeno. |
TW201437200A (zh) | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
SG11201507459YA (en) * | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
WO2015066456A1 (en) | 2013-10-31 | 2015-05-07 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa-1 receptor |
CA2953472C (en) | 2014-06-27 | 2022-08-02 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound salt |
-
2014
- 2014-03-17 SG SG11201507459YA patent/SG11201507459YA/en unknown
- 2014-03-17 CA CA2906931A patent/CA2906931C/en active Active
- 2014-03-17 KR KR1020157028061A patent/KR102090231B1/ko active IP Right Grant
- 2014-03-17 PT PT147625552T patent/PT2988743T/pt unknown
- 2014-03-17 MX MX2015013303A patent/MX2015013303A/es unknown
- 2014-03-17 ES ES14762555T patent/ES2855173T3/es active Active
- 2014-03-17 DK DK14762555.2T patent/DK2988743T3/da active
- 2014-03-17 EP EP14762555.2A patent/EP2988743B1/en active Active
- 2014-03-17 EA EA201591607A patent/EA033923B1/ru unknown
- 2014-03-17 CN CN201480015333.XA patent/CN105142635B/zh active Active
- 2014-03-17 AU AU2014232383A patent/AU2014232383B2/en active Active
- 2014-03-17 WO PCT/US2014/030712 patent/WO2014145873A2/en active Application Filing
- 2014-03-17 US US14/776,954 patent/US10000459B2/en active Active
- 2014-03-17 JP JP2016503448A patent/JP6482086B2/ja active Active
- 2014-03-17 SG SG10201803833WA patent/SG10201803833WA/en unknown
- 2014-03-17 BR BR112015023267-1A patent/BR112015023267B1/pt active IP Right Grant
-
2016
- 2016-08-05 HK HK16109390.9A patent/HK1221167A1/zh unknown
-
2018
- 2018-06-05 US US16/000,283 patent/US10570103B2/en active Active
- 2018-06-18 US US16/010,755 patent/US10526298B2/en active Active
-
2019
- 2019-02-07 JP JP2019020553A patent/JP6843903B2/ja active Active
- 2019-04-17 AU AU2019202731A patent/AU2019202731B2/en active Active
- 2019-06-18 US US18/015,289 patent/US20230286928A1/en active Pending
- 2019-06-18 CN CN201980047732.7A patent/CN112424174B/zh active Active
- 2019-06-18 SG SG11202012656WA patent/SG11202012656WA/en unknown
- 2019-06-18 BR BR112020025927-6A patent/BR112020025927A2/pt unknown
- 2019-06-18 MX MX2020014300A patent/MX2020014300A/es unknown
- 2019-06-18 AU AU2019288275A patent/AU2019288275A1/en active Pending
-
2020
- 2020-02-07 US US16/784,486 patent/US11427552B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591607A8 (ru) | Гетероциклические соединения, применимые в лечении заболеваний | |
RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
PE20170695A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
EA201791002A1 (ru) | Новые соединения, модулирующие fxr (nr1h4) | |
EA201591908A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы | |
EA201690066A1 (ru) | Соединения пиримидиндиона | |
CY1121421T1 (el) | Φαρμακοτεχνικες μορφες | |
EA202091120A2 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
EA201291167A1 (ru) | Замещенные гетероциклилбензилпиразолы и их применение | |
MX2019014935A (es) | Antagonistas muscarinicos y sus combinaciones para el tratamiento de enfermedades de las vias respiratorias en caballos. | |
EA201790905A1 (ru) | Способ лечения состояний, связанных с рецептором pgi2 | |
EA201390070A1 (ru) | Лечение расстройств, вызванных l-dopa, дофаминовым агонистом и/или усилителем дофамина | |
EA201791021A1 (ru) | 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ | |
MX2019006773A (es) | Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros. | |
MX2018007143A (es) | Formas de sales y polimorfos de (r)-1-(4-(6-(2-(4-(3,3-difluorocic lobutoxi)-6-metilpiridin-2-il)acetamido)piridazin-3-il)-2-fluorob util)-n-metil-1h-1,2,3-triazol-4-carboxamida. | |
WO2014081709A3 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
EA201992121A1 (ru) | Гетероциклические соединения, применимые в лечении заболеваний | |
EA201792558A1 (ru) | Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль | |
BR112013021750A2 (pt) | uso de ácido 4-{[4-({[4-(2,2,2-trifluoretoxi)-1,2-benzisoxazol-3-il]-oxi}metil)piperidina-1-il]metil}tetrahidro-2h-pirano-4-carboxílico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para o tratamento de doenças gastrointestinais, método para o tratamento de doenças gastrointestinais em um sujeito animal, incluindo um sujeito mamífero, método para o tratamento de doenças gastrointestinais e ácido 4-{[4-({[4-(2,2,2-trifluoretoxi)-1,2-benzisoxazol-3-il]-oxi}metil)piperidina-1-il]metil}tetrahidro-2h-pirano-4-carboxílico ou um sal farmaceuticamente aceitável do mesmo | |
WO2012163088A3 (zh) | 肾病和心脏病的治疗药物及其用途 | |
EA201991990A1 (ru) | Фармацевтические композиции для комбинированной терапии | |
EA201690762A1 (ru) | {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек | |
MD1094Z (ru) | Метод диагностики гастроэзофагеальной рефлюксной болезни | |
Li-Sha et al. | PW061 Effects of Carvedilol Treatment on Cardiac Camp Response Element Binding Protein Expression and Phosphorylation in Acute Coxsackievirus B3-Induced Myocarditis |